New data from a pooled analysis shows improved overall survival for prostate cancer patients treated with FIRMAGON® (degarelix) compared to LHRH agonists

Saint-Prex, Switzerland – 25 November 2014 –

New data published in the December issue of the European Journal of Urology indicates improvement in overall survival (OS) and prostate specific antigen progression free survival (PSA PFS) for degarelix (FIRMAGON®), a gonadotropin releasing hormone (GnRH) antagonist, compared to commonly prescribed luteinising hormone-releasing hormone (LHRH) agonists. In addition, the data showed a reduction in the incidence of joint, musculoskeletal and urinary tract adverse events for those men with prostate cancer treated with degarelix rather than LHRH agonists. However, the overall rate of any adverse event (including hot flush and injection-site reactions) was higher in the degarelix group than the LHRH agonist group.

Results showed a 29% improvement in PSA PFS* (p=0.017) and 53% improvement in overall survival (p=0.023) for men with prostate cancer who were treated with degarelix instead of an LHRH agonist.

Lead study author Professor Laurence Klotz, MD, Sunnybrook Health Sciences Centre, University of Toronto, Canada, said, “These pooled data showed degarelix improved overall survival rates compared to LHRH agonists. This is encouraging for physicians making treatment decisions for their prostate cancer patients.”

These findings are based on a pooled analysis of 1,925 men with prostate cancer from five prospective, phase III or IIIb randomised trials.¹ Men requiring androgen deprivation therapy for the treatment of prostate cancer received degarelix (n=1,266) or an existing LHRH agonist (goserelin, n=458; leuprolide, n=201). The full analysis set used for efficacy analysis consisted of 1,920 patients. Of those, 1,263 received degarelix, 456 goserelin and 201 leuprolide. Those patients being treated with degarelix received a 240 mg dose in all trials and most patients received a maintenance dose of 80 mg. The majority of patients (1,458) received treatment for one year, while the remaining patients were treated for three months.

In terms of disease-related adverse events, for those patients taking degarelix, there were significantly fewer musculoskeletal events (p=0.007) and a significantly lower incidence of any urinary tract infections (p=0.023) compared to the LHRH agonist-treated patients. In addition, in the degarelix group there were fewer patients that experienced a fracture (p=0.064) (although this was not statistically significant) and there were significantly less frequent joint-related signs and symptoms (p=0.041) compared to the LHRH agonist treatment arm.

The overall rate of any adverse event was significantly higher in the degarelix group (74%) compared to the LHRH agonist group (68%), (p=0.002). Specifically, hot flush and injection-site reactions, including pain, erythema, swelling and nodules, were more frequent in the degarelix group.

FIRMAGON® (degarelix) was approved for the treatment of advanced hormone-dependent prostate cancer in both the EU and US in 2009. Today it is available in approximately 40 countries around the world, including a growing number in Asia, Latin America and the Middle East.

– ENDS –

About FIRMAGON®

FIRMAGON® has chemical characteristics and a novel mechanism of action, different from traditionally used hormonal therapies. Administered as a deep subcutaneous injection, FIRMAGON® rapidly reduces levels of testosterone by blocking the GnRH receptors in the pituitary gland. Blocking the receptors suppresses the release of the luteinising hormone and follicle-stimulating hormone, resulting in a decrease in production of testosterone by the testicles to castration levels within three days. Prostate cancer is dependent on testosterone for its growth, and reducing testosterone levels slows the growth of cancer cells.

In clinical trials FIRMAGON® was generally well tolerated. Common side effects are hot flushes, injection site pain and erythema, increased weight, nasopharyngitis, fatigue and back pain.²

About Prostate Cancer

Prostate cancer is the most common form of male cancer in the western world,³ and the second leading cause of cancer death in men in some countries.⁴ Around 417,000 new cases of prostate cancer are diagnosed in Europe each year. Worldwide this figure rises to 1.1 million new cases.⁵

For further media information and news alerts on prostate cancer please visit Ferring’s information website www.ProstateCancerLiving.com.

About Ferring

Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

To learn more about Ferring or its products please visit www.ferring.com.

For more information, please contact

Emma Coughlan
Tonic Life Communications
+44 (0) 7896 075431
emma.coughlan@toniclc.com

Patrick Gorman
Ferring Pharmaceuticals
+41 (0) 58 301 00 53
patrick.gorman@ferring.com

© 2013 Ferring B.V.
FIRMAGON® is a trademark owned by Ferring B.V.

References

1. Klotz,L. et al. Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomised Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists, European Urology. 66(6), p. 1101-1108
2. Van Poppel H, De La Rosette JJ, Persson B.E et al. Degarelix Study Group; Long-term evaluation of degarelix, a gonadotrophin-releasing hormone (GnRH) receptor blocker, investigated in a multicentre randomised study in prostate cancer (CAP) patients. Abstract (23.) Euro Urology Supplement 2007;6(2):28
3. University of Iowa Hospitals and Clinics. Available at: http://www.medicine.uiowa.edu/ [Accessed 02 April 2014]
4. American Cancer Society. Available at:
   http://www.cancer.org/docroot/cri/content/cri_2_4_1x_what_are_the_key_statistics_for_prostate_cancer_36.asp [Accessed 02 April 2014]
5. Publications. Cancer Research UK. Available at http://publications.cancerresearchuk.org/downloads/product/CS_KF_PROSTATE.pdf [Accessed 24 November 2014]

CORTIMENT®MMX®, a new treatment for ulcerative colitis, receives European approval

Saint-Prex, Switzerland – 20 October 2014 –

Ferring Pharmaceuticals announced today that its CORTIMENT^® MMX® (budesonide) treatment for the induction of remission in patients with active, mild to moderate ulcerative colitis¹ has received marketing approval from 27 European Union member states² following the EU Mutual Recognition Procedure. CORTIMENT has been commercially available in the Netherlands since November 2013. Ferring plans to begin launching the product in the 27 additional European countries in the coming months.

CORTIMENT contains budesonide, a locally acting glucocorticosteroid, in a novel oral tablet formulation utilizing MMX^® multimatrix colonic delivery technology. The approved dosing regimen for adult patients is one 9 mg tablet taken once daily for up to 8 weeks. In phase III studies, 2.4 to 3.9 times more patients achieved clinical and endoscopic remission with CORTIMENT compared to placebo, and no clinically significant glucocorticosteroid side effects were seen versus placebo after eight weeks of treatment (CORE I study and CORE II study respectively).³

CORTIMENT has been developed by Cosmo Pharmaceuticals SpA. Ferring is the licensee in the EU and Asia (excluding Japan), Australia, Canada, Latin America and Africa. In the United States, where the product is available as UCERIS^®, the licensee is Salix Pharmaceuticals, Inc.

Dr. Simon Travis, Consultant Gastroenterologist at Oxford University and the John Radcliffe Hospital, UK said: “Well over two million people in Europe suffer from ulcerative colitis. CORTIMENT, with its proven efficacy and safety profile, will provide an important new option for physicians treating active, mild to moderate ulcerative colitis.”

Michel Pettigrew, President of the Executive Board and COO at Ferring commented: “Bringing relief to sufferers of inflammatory bowel disease (IBD) is a key area of focus for Ferring as evidenced by our PENTASA^® (mesalazine) range of IBD treatments. With the launch of CORTIMENT, a new treatment with a novel formulation for active mild to moderate ulcerative colitis, we will expand our portfolio and build on our commitment to innovation in gastroenterology.”

– ENDS –

About CORTIMENT^®MMX®

CORTIMENT is a locally acting corticosteroid in a novel, patented, oral tablet formulation, which utilizes MMX^® multi-matrix technology and is designed to result in the controlled release and distribution of budesonide throughout the length of the colon. Budesonide has mainly topical anti-inflammatory activity and due to its high first pass metabolism, it has low systemic bioavailability. CORTIMENT is indicated in adults for induction of remission in patients with mild to moderate active ulcerative colitis where 5-ASA (aminosalicylate) treatment is not sufficient. Some patients may benefit from initial treatment with CORTIMENT when recommended by their doctor. CORTIMENT may be marketed under other names in some countries.

About Ulcerative Colitis

Ulcerative colitis is a form of inflammatory bowel disease (IBD) that produces inflammation and ulcers along the inside of the colon. The inflammation can interfere with the normal function of the colon, often causing cramping, bloating, diarrhoea, bleeding, fatigue, weight loss and frequent bowel movements, which may also strongly affect quality of life. It is believed that 1.5 million in European Union and 2.1 million in the total European population suffer from ulcerative colitis⁴.

Ulcerative Colitis is a chronic relapsing-remitting illness for which there is no known cure, but with appropriate treatment patients can manage their symptoms. However, it is estimated that up to 30% of patients with mild or moderate ulcerative colitis do not respond sufficiently to aminosalicylate (5-ASA) drugs and require a different or add on therapy. Patients refractive to treatment with 5-ASA drugs typically receive a course of a systemically absorbed corticosteroid, the success of which may be limited by significant side effects. For moderate to severe cases of ulcerative colitis, immunosuppressant drugs or biologic drugs may be prescribed. If the condition does not respond to pharmaceutical therapy and the symptoms are severe, the patient may be referred for surgery.

About Ferring Pharmaceuticals

Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

To learn more about Ferring or its products please visit www.ferring.com.

FERRING, CORTIMENT and PENTASA are trademarks of Ferring B.V. MMX is a trademark of Cosmo Pharmaceuticals SpA. UCERIS is a registered trademark of Santarus, Inc, a wholly owned subsidiary of Salix Pharmaceuticals, Inc.

For more information, please contact

Patrick Gorman
+41 58 301 0053
patrick.gorman@ferring.com

References

1. See about the CORTIMENT^®MMX® section (above) for the full indication.
2. Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Finland, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Norway, Poland, Portugal, Romania, Slovenia, Slovakia, Spain, Sweden, United Kingdom
3. Travis SP, Danese S, Kupcinskas L et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 2013; Sandborn WJ, Travis S, Moro L et al. Once-daily budesonide MMX(R) extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012;143:1218-26.e1
4. Burisch J, Jess T, Martinato M, Lakatos P on behalf of ECCO –EpiCom. The burden of inflammatory bowel disease in Europe. Journal of Crohn’s and Colitis – 1 May 2013 (Vol. 7, Issue 4, Pages 322-337, DOI: 10.1016/j.crohns.2013.01.010)

The Scottish Medicines Consortium (SMC) accepts MYSODELLE® for use in NHS Scotland

U.K. – 13 October 2014 –

Ferring Pharmaceuticals Ltd, U.K. announced today that the Scottish Medicines Consortium (SMC) has accepted its new product MYSODELLE® (misoprostol), a retrievable, controlled-release vaginal insert for use in NHS Scotland. MYSODELLE is indicated for the induction of labour in women with an unfavourable cervix*, from 36 weeks of gestation, in whom induction is clinically indicated.

MYSODELLE was approved via a European Decentralised Procedure involving 29 Member States of the European Economic Area (EEA) based on the results of the pivotal EXPEDITE study¹. The Medicines and Healthcare products Regulatory Agency (MHRA) adopted the decision and granted a National Marketing Authorization in November 2013.

MYSODELLE has been specifically developed and approved for labour induction and it is the only licensed controlled-release, retrievable insert containing misoprostol. The decision made by the SMC marks an important step in enhancing the care and experience of women who are being induced for labour.

UK General Manager of Ferring Pharmaceuticals, Steve Howson said, “We are excited to launch our controlled-release formulation of misoprostol for labour induction, a procedure which is becoming increasingly common in the UK. This introduction demonstrates Ferring’s ongoing commitment to develop new and clinically significant treatments in the field of reproductive health and obstetrics”.

“Many maternity units are stretched with limited midwifery and physical bed capacity which sometimes lead to temporary closures of delivery suites. MYSODELLE could potentially help relieve some of the pressures on midwifery time and bed capacity.”

“The misoprostol vaginal insert is an important development to help manage the induction of labour for many of our couples, especially those who experience prolonged inductions, said Kirsty Dundas, Consultant Obstetrician, Royal Infirmary of Edinburgh. “The treatment should help improve our processes and provide a better service with its much quicker time to delivery.”

As well as reviewing the clinical and safety evidence for MYSODELLE, the SMC reviewed the comparative health economic evidence and stated that the economic case for MYSODELLE has been demonstrated.

– ENDS –

About MYSODELLE

MYSODELLE consists of a single administration, retrievable controlled-release vaginal insert with a dosing reservoir of 200 micrograms of misoprostol. Misoprostol is released at a mean rate of approximately 7 micrograms/hour over a period of 24 hours. Drug release continues as long as MYSODELLE® is in the vagina. The product is equipped with a retrieval tape that enables rapid removal.

Misoprostol is a synthetic prostaglandin E1 (PGE1) analogue. The World Health Organization (WHO) recommends prostaglandins for cervical ripening and labour induction and misoprostol is one of the compounds on the “WHO essential drug list” for labour induction. Many current clinical guidelines also recommend the use of prostaglandins for the induction of labour.^4,7 The NICE UK guidelines currently recommend vaginal PGE2 as the preferred method of induction of labour.

About the EXPEDITE study

The decentralised submission was based on the results of clinical studies in more than 3,000 pregnant women at term, including the EXPEDITE study.¹ It was a phase III, randomized, double-blind, multicentre study conducted in the U.S., which compared the 200mcg misprostol vaginal insert (MVI) (n=678) with the 10-mg dinoprostone vaginal insert (DVI) (n=680) in terms of efficacy and safety in induction of labour in pregnant women with an unfavourable cervix.
Women treated with MVI (misoprostol) had significantly shorter median time to vaginal delivery (primary endpoint) than the women treated with DVI (21.5 hours [95% CI: 20.0–23.4] vs 32.8 hours [95% CI: 30.2–34.9]; p<0.001, respectively). They also had significantly decreased overall median time to any delivery (18.3h vs 27.3h, p<0.001) and overall median time to onset of active labour (12.1h vs 18.6h p<0.001) compared with the women treated with DVI. Fewer women treated with MVI received pre-delivery oxytocin (48.1% vs 74.1% p<0.001).
The rates of caesarean delivery, co-primary safety endpoint, were similar between MVI and DVI (26.0% vs. 27.2%; p = 0.65).

About labour induction

Labour induction is defined as the artificial initiation of labour.⁸ It is generally indicated when the risk to either the mother or the foetus outweighs the possible benefits of continuing to manage the pregnancy. In the UK, the incidence of labour induction has increased to approximately 20% of all pregnancies.⁸ One possible explanation for this trend is the association between increased maternal age and complication rates.⁸ In the U.K. vaginal PGE2 is the preferred pharmacological method for induction of labour.⁴ Prostaglandins have been shown to be efficacious in both cervical ripening and labour induction. Several clinical guidelines recommend prostaglandins for use in labour induction.^2,3,4 If vaginal PGE2 is contraindicated for any reason, amniotomy (alone or with oxytocin) may be offered ⁴.Membrane sweeping is regarded as an adjunct to the process of induction of labour. It involves the examining finger passing through the cervix to rotate against the wall of the uterus, to separate the chorionic membrane from the deciduas.⁴

About Ferring Pharmaceuticals

Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The Ferring product portfolio demonstrates an exceptionally innovative and successful track record in the fields of Urology, Endocrine Oncology, Gastroenterology, Endocrinology (Growth) and Reproductive Health (Infertility and Obstetrics). The common thread is that the Company remains focused on producing treatments that enable doctors to treat patients on the body’s own terms. Ferring has its own operating subsidiaries in 55 countries and markets its products in more than 100 countries.

For more information visit www.ferring.co.uk.

* An unfavourable cervix is a cervix that has not yet softened and thinned so that dilation can take place.

For more information, please contact

Steve Howson
General Manager, Ferring Pharmaceuticals (UK) Ltd.
+44 208 580 4199

All trademarks mentioned above are property of Ferring B.V.

References

1. Wing DA, Brown R, Plante LA et al. Misoprostol Vaginal Insert and Time to Vaginal Delivery. A randomized Controlled Trial. Obstet Gynecol 2013; 122: 201-9. Web address:
   http://journals.lww.com/greenjournal/Fulltext/2013/08000/Misoprostol_Vaginal_Insert_and_Time_to_Vaginal.4.aspx
2. Kjaergaard H, Foldgast AM, Dykes AK. Experiences of non-progressive and augmented labour among nulliparous women: a qualitative interview study in a Grounded Theory approach. BMC Pregnancy Childbirth. 2007;7:15
3. Cheng YW, et al. Obstet Gynecol 2010;116:1127-1135. (PubMed)
4. NICE Clinical guidelines – Induction of labour, July 2008.
   http://www.nice.org.uk/nicemedia/live/12012/41255/41255.pdf
5. ACOG practice Bulletin – Induction of labour, August 2009.
   http://www.ohsu.edu/som/obgyn/programs/ACOG%20Practice%20Bulletein%20107%202009.pdf
6. WHO Recommendation for Induction of labour, 2011.
   http://whqlibdoc.who.int/publications/2011/9789241501156_eng.pdf
7. SOGC Clinical practice Guideline Induction of Labour, September 2013.
   http://sogc.org/wp-content/uploads/2013/08/September2013-CPG296-ENG-Online_REV-D.pdf
8. Carolan M, Davey MA, Biro MA, Kealy M. Older Maternal Age and Intervention in Labor: A Population-Based Study Comparing Older and Younger First-Time Mothers in Victoria, Australia. Birth 2011; 38:24–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/?term=Carolan+M%2C+Davey+MA%2C+Biro+MA%2C+Kealy+M.+Older+Maternal+Age+and+Intervention+in+Labor%3A+A+Population-Based+Study+Comparing+Older+and+Younger+First-Time+Mothers+in+Victoria%2C+Australia.+Birth

Ferring Pharmaceuticals and Roche collaborate to develop personalised infertility treatment

Ferring’s follicle-stimulating hormone is in development with a companion diagnostic test from Roche to help improve the clinical management of infertility treatment

Saint-Prex, Switzerland – 24 June 2014 –

Ferring Pharmaceuticals and Roche have announced a collaboration to combine diagnostic testing technology from Roche with Ferring’s human cell line derived recombinant follicle-stimulating hormone (human rFSH), a gonadotrophin currently in phase III development. This combination is intended to make it possible for healthcare professionals to personalise infertility treatment to a woman’s specific needs.

Under the terms of the worldwide agreement, Roche will work with Ferring and its global phase III programme to qualify, validate, document and seek regulatory approval for a companion diagnostic test to be used in combination with Ferring’s human rFSH.

Currently under development with Ferring’s human rFSH, the fully-automated Elecsys® AMH assay from Roche aims to assess anti-Müllerian hormone (AMH) levels, a measure of a woman’s ovarian reserve and also of her ovarian response to infertility treatment with gonadotrophin. With this information, doctors will be better able to deliver a personalised dose of Ferring’s human rFSH based on the woman’s AMH level. Unlike manual AMH testing that can take up to several hours to produce results, the fully automated Elecsys AMH test determines hormone levels in 18 minutes, making it appropriate for routine clinical use.¹

“The ability to tailor a specific dose of gonadotrophin based on a woman’s personal AMH level would represent a major step forward in fertility management,” said Pascal Danglas, MD, Executive Vice President, Clinical and Product Development at Ferring. “This collaboration demonstrates Ferring’s commitment to researching and developing innovative treatment options for infertility.”

Personalised dosing according to a woman’s AMH level, if successful, may improve the predictability of infertility treatment and, as a result, lower the potential burden of treatment for women seeking to conceive through assisted reproductive technology.

“As a leader in personalised healthcare we are expanding this approach to ever more areas of unmet medical need such as infertility and women’s health. In collaboration with Ferring, we are excited to play a pioneering role in individualising fertility management while continuing to invest in medically differentiated tests,” said Jean-Claude Gottraux, Head of Roche Professional Diagnostics.

This unique approach in personalised medicine may provide an improved option for couples seeking to conceive through in vitro fertilization.

– ENDS –

About the phase III clinical study

A multinational clinical phase III comparative study is already underway to confirm the efficacy and safety of Ferring’s human cell line derived rFSH in a personalised treatment regimen based on the woman’s AMH levels. The ESTHER (Evidence-based Stimulation Trial with Human rFSH in Europe and Rest of World) programme will enrol 1150 patients from 11 countries and from over 30 sites during 2014 and 2015. Additional studies are planned for US, Japan, China and other parts of Asia.

About Ferring Pharmaceuticals

Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in 55 countries and markets its products in more than 100 countries.

To learn more about Ferring or its products please visit www.ferring.com.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the WHO Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

For more information, please contact

Ferring Pharmaceuticals

Patrick Gorman
Ferring Pharmaceuticals
+41 (0) 58 301 00 53
patrick.gorman@ferring.com

Roche

Dr Daniel Fleiter
Roche Diagnostics International Ltd
+41 (0) 41 798 59 90
daniel.fleiter@roche.com

References

1. Gassner D, Jung R: First fully automated immunoassay for anti-Müllerian hormone. Clin Chem Lab Med. 2014 Mar 13. pii: /j/cclm.ahead-of-print/cclm-2014-0022/cclm-2014-0022.xml. doi: 10.1515/cclm-2014-0022. [Epub ahead of print]

Ferring launches Guts4life, an interactive online resource for people with inflammatory bowel disease

Saint-Prex, Switzerland – 19 May 2014 –

Ferring Pharmaceuticals marks World IBD Day (May 19th) with the launch of Guts4life (www.guts4life.com), a new interactive website with information, support and inspiration for people concerned with Crohn’s disease and ulcerative colitis, conditions known as inflammatory bowel diseases (IBD). IBD describes a range of chronic diseases of the gastrointestinal system characterised by intermittent flares with debilitating symptoms that can affect a patient’s quality of life and lead to emotional distress and social isolation. Guts4life was designed together with IBD patients to provide support and encouragement throughout the IBD journey – from bowel symptom worries, to diagnosis, through managing and living with IBD.

“Being diagnosed with IBD can be a life changing event for the patient but also friends and family,” said Dr. Johan Masure, Global Medical Director, Gastroenterology/Endocrinology at Ferring. “With Guts4Life aimed at IBD sufferers and those close to them, Ferring aims to provide information that will increase understanding of the condition and how best to handle it.”

Guts4life includes:

• Information for people worried about bowel problems including an interactive “Symptom Checker”
• Detailed descriptions of IBD and its two main types: Ulcerative colitis and Crohn’s disease
• Advice on how to manage and live with IBD including an interactive “Wellbeing Tool”
• Inspiring real life stories on how others have lived rich, full and productive lives with IBD

Martin Kojinkov, of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA), said “With deep information and useful features, I believe Guts4life will be an important resource for IBD patients.”

Elisabeth Weis, Senior Director, Global Marketing, Gastroenterology/Endocrinology at Ferring added “Ferring is committed to making a difference in people’s health and quality of life. We were pleased to work with the European Federation of Crohn’s and Ulcerative Colitis Associations in developing Guts4life for the benefit of IBD patients and their families.”

To learn more, visit www.guts4life.com.

– ENDS –

About Ferring Pharmaceuticals

Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in 55 countries and markets its products in more than 100 countries.

To learn more about Ferring or its products please visit www.ferring.com.

For more information, please contact

Patrick Gorman
Ferring Pharmaceuticals
+41 (0) 58 301 00 53
patrick.gorman@ferring.com